It would be worthwhile to take a closer look at Zentalis Pharmaceuticals Inc (ZNTL)

While Zentalis Pharmaceuticals Inc has underperformed by -6.42%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ZNTL fell by -15.39%, with highs and lows ranging from $31.46 to $9.56, whereas the simple moving average fell by -18.96% in the last 200 days.

On November 08, 2023, Wedbush Downgraded Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) to Neutral. A report published by Leerink Partners on November 07, 2023, Downgraded its rating to ‘Market Perform’ for ZNTL. Wells Fargo Initiated an Overweight rating on April 06, 2022, and assigned a price target of $67. Jefferies initiated its ‘Buy’ rating for ZNTL, as published in its report on October 07, 2021. Stifel’s report from September 30, 2021 suggests a price prediction of $84 for ZNTL shares, giving the stock a ‘Buy’ rating. Oppenheimer also rated the stock as ‘Outperform’.

Analysis of Zentalis Pharmaceuticals Inc (ZNTL)

Zentalis Pharmaceuticals Inc’s future performance can be determined with the help of several well-rounded types of analysis and research techniques, with equity being one of the most influential. The goal here is to ensure that your current return on equity of -67.09% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 7.16, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.

The average volume for any stock is also a very valuable indicator of volatility, and ZNTL has an average volume of 823.57K. On a monthly basis, the volatility of the stock is set at 7.05%, whereas on a weekly basis, it is put at 6.24%, with a loss of -5.70% over the past seven days. Furthermore, long-term investors anticipate a median target price of $33.56, showing growth from the present price of $14.73, which can serve as yet another indication of whether ZNTL is worth investing in or should be passed over.

How Do You Analyze Zentalis Pharmaceuticals Inc Shares?

In addition to analyzing the fundamentals, it is also important to look at how many company employees own stock. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 10.05%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 109.93% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.

ZNTL shares are owned by institutional investors to the tune of 109.93% at present.

Related Posts